Alzheimer's disease (AD) is the main cause of dementia, with its diagnosis and management remaining challenging. Amyloid positron emission tomography (PET) has become increasingly important in medical practice for patients with AD. To integrate and update previous guidelines in the field, a task group of experts of several disciplines from multiple countries was assembled, and they revised and approved the content related to the application of amyloid PET in the medical settings of cognitively impaired individuals, focusing on clinical scenarios, patient preparation, administered activities, as well as image acquisition, processing, interpretation and reporting. In addition, expert opinions, practices, and protocols of prominent research institutions performing research on amyloid PET of dementia are integrated. With the increasing availability of amyloid PET imaging, a complete and standard pipeline for the entire examination process is essential for clinical practice. This international consensus and practice guideline will help to promote proper clinical use of amyloid PET imaging in patients with AD.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425321 | PMC |
| http://dx.doi.org/10.1007/s43657-022-00068-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Establishing cutoff values for visual amyloid positivity in [F]flutemetamol PET.
EJNMMI Res
January 2025
Department of Nuclear Medicine and Molecular Imaging, Ajou University School of Medicine, Suwon, Korea.
Background: This study aimed to establish the optimal cutoff values for visual amyloid positivity using standardized uptake value ratios (SUVRs) in [F]flutemetamol (FMM) positron emission tomography (PET) imaging. Given the variability in amyloid assessment, our goal was to determine cutoff values that enhance diagnostic accuracy and assist clinicians in reliably identifying amyloid positivity.
Results: The identified cutoff values for visual amyloid positivity were > 1.
Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.
Alzheimers Dement
January 2025
Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Introduction: The Alzheimer's Association and the Society of Nuclear Medicine and Molecular Imaging convened a multidisciplinary workgroup to update appropriate use criteria (AUC) for amyloid positron emission tomography (PET) and to develop AUC for tau PET.
Methods: The workgroup identified key research questions that guided a systematic literature review on clinical amyloid/tau PET. Building on this review, the workgroup developed 17 clinical scenarios in which amyloid or tau PET may be considered.
Experiences from Clinical Research and Routine Use of Florbetaben Amyloid PET-A Decade of Post-Authorization Insights.
Pharmaceuticals (Basel)
December 2024
Life Molecular Imaging GmbH, Tegeler Str. 7, 13353 Berlin, Germany.
Florbetaben (FBB) is a radiopharmaceutical approved by the FDA and EMA in 2014 for the positron emission tomography (PET) imaging of brain amyloid deposition in patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) or other causes of cognitive decline. Initially, the clinical adoption of FBB PET faced significant barriers, including reimbursement challenges and uncertainties regarding its integration into diagnostic clinical practice. This review examines the progress made in overcoming these obstacles and describes the concurrent evolution of the diagnostic landscape.
View Article and Find Full Text PDFEnhancing Amyloid PET Quantification: MRI-Guided Super-Resolution Using Latent Diffusion Models.
Life (Basel)
December 2024
School of Computing and Augmented Intelligence, Arizona State University, Tempe, AZ 85281, USA.
Amyloid PET imaging plays a crucial role in the diagnosis and research of Alzheimer's disease (AD), allowing non-invasive detection of amyloid-β plaques in the brain. However, the low spatial resolution of PET scans limits the accurate quantification of amyloid deposition due to partial volume effects (PVE). In this study, we propose a novel approach to addressing PVE using a latent diffusion model for resolution recovery (LDM-RR) of PET imaging.
View Article and Find Full Text PDFPorous Materials for Early Diagnosis of Neurodegenerative Diseases.
Adv Healthc Mater
January 2025
Department of Biomaterials, Saveetha Dental College and Hospitals, SIMATS, Saveetha University, Chennai, 600077, India.
Neurodegenerative diseases, particularly Alzheimer's disease and Parkinson's disease, present formidable challenges in modern medicine due to their complex pathologies and the absence of curative treatments. Despite advances in symptomatic management, early diagnosis remains essential for mitigating disease progression and improving patient outcomes. Traditional diagnostic methods, such as MRI, PET, and cerebrospinal fluid biomarker analysis, are often inadequate for the early detection of these diseases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!